MITO-11: A Randomized Multicentre Phase II Trial With Pazopanib and Weekly Paclitaxel vs Weekly Paclitaxel in Platinum Resistant or Refractory Ovarian Cancer

Trial Profile

MITO-11: A Randomized Multicentre Phase II Trial With Pazopanib and Weekly Paclitaxel vs Weekly Paclitaxel in Platinum Resistant or Refractory Ovarian Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Pazopanib (Primary) ; Paclitaxel
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Acronyms MITO - 11; MITO-11
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 28 Oct 2015 Planned End Date changed from 1 Sep 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 08 Apr 2015 Planned End Date changed from 1 Sep 2014 to 1 Sep 2015, as reported by ClinicalTrials.gov.
    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top